An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance Pharmacokinetics Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

Trial Profile

An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance Pharmacokinetics Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Hitanercept (Primary) ; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 08 Oct 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top